INMUNE BIO INC. Proceeds from Debt, Net of Issuance Costs
INMUNE BIO INC. (INMB) reported Proceeds from Debt, Net of Issuance Costs of $775.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-10-30
- 2025-09-30: Proceeds from Debt, Net of Issuance Costs 9 month $775.00K.
- 2021-07-01: Proceeds from Debt, Net of Issuance Costs $36.90M.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 9 month |
|---|---|---|
| 2025-09-30 | $775.00K 10-Q · filed 2025-10-30 | |
| 2021-07-01 | $36.90M 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |